Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187590 · ClinicalTrials.gov registry record · NA
A Case Management Intervention to Prevent ER Visits in HIV-infected Persons
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 612
- Enrollment target
NCT00187590: Clinical Trial NA study, sponsored by University of California, San Francisco.
NCT00187590 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 612 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00187590, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 612 participants
- Enrollment target
Study Summary
Case management has become an integral part of HIV care. There is little science however demonstrating its effectiveness. This is a randomized, controlled trial of a phone call intervention after an ER visit to see if this can reduce further ER visits, hospitalizations, deaths, and cost.
Interventions
- BEHAVIORAL Case manager phone call after an ER visit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2004-04 |
| Est. Completion | 2013-01 |
| Phase | NA |
Why NCT00187590 stopped before completion
NCT00187590 is an interventional study that assigns participants to a tested intervention. The registered 612 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which Case manager phone call after an ER visit is the first listed.
NCT00187590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00187590 about?
NCT00187590 is a clinical study titled "A Case Management Intervention to Prevent ER Visits in HIV-infected Persons". Case management has become an integral part of HIV care. There is little science however demonstrating its effectiveness. This is a randomized, controlled trial of a phone call intervention after an ER visit to see if this can reduce further ER visits, hospitalizations, deaths, and cost.
What is the current status of trial NCT00187590?
This trial is currently terminated. It is a NA study. The enrollment target is 612 participants. The study started on 2004-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00187590?
The interventions under investigation include: Case manager phone call after an ER visit (BEHAVIORAL).
Who is sponsoring clinical trial NCT00187590?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00187590's enrollment target sits among peer trials
612 161st of 2000 higher than 1,840 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT04590326 · 612 participants · Phase 1
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- NCT06266416 · 612 participants · NA
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia